Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits

被引：44
作者：
Capilla, J
Yustes, C
Mayayo, E
Fernández, B
Ortoneda, M
Pastor, FJ
Guarro, J
机构：
[1] Univ Rovira & Virgili, Fac Med, Unitat Microbiol, E-43201 Reus, Spain
[2] Univ Rovira & Virgili, Fac Med, Unitat Anat Patol, E-43201 Reus, Spain
[3] Hosp Univ Terragona Joan XXIII, Serv Patol, Tarragona, Spain
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2003年 / 47卷 / 06期
关键词：
D O I：
10.1128/AAC.47.6.1948-1951.2003
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
There are no effective therapeutics for treating invasive Scedosporium prolificans infections. Doses of 15, 25, and 50 mg/kg of body weight/day for the new triazole albaconazole (ABC) were evaluated in an immunocompetent rabbit model of systemic infection with this mold. Treatments were begun 1 day after challenge and given for 10 days. ABC at any dose was more effective than amphotericin B (AMB) at 0.8 mg/kg/day at clearing S. prolificans from tissue (P < 0.007). The percentages of survival at 25 mg of ABC/kg/day were similar to those obtained with AMB. Rabbits showed 100% survival when they were treated with 50 mg of ABC per kg (P < 0.0001 versus control group), and only this dosage was able to reduce tissue burden significantly in the five organs studied, i.e., spleen, kidneys, liver, lungs, and brain.
引用
收藏
页码：1948 / 1951
页数：4
相关论文
共 23 条
[1]   New azole antifungals.: 3.: Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones [J].
Bartroli, J ;
Turmo, E ;
Algueró, M ;
Boncompte, E ;
Vericat, ML ;
Conte, L ;
Ramis, J ;
Merlos, M ;
García-Rafanell, J ;
Forn, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (11) :1869-1882
[2]   Deep infections caused by Scedosporium prolificans - A report on 16 cases in Spain and a review of the literature [J].
Berenguer, J ;
RodriguezTudela, JL ;
Richard, C ;
Alvarez, M ;
Sanz, MA ;
Gaztelurrutia, L ;
Ayats, J ;
MartinezSuarez, JV .
MEDICINE, 1997, 76 (04) :256-265
[3]  
CANO J, 1992, J MED VET MYCOL, V30, P413
[4]   In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi [J].
Capilla, J ;
Ortoneda, M ;
Pastor, FJ ;
Guarro, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) :2635-2637
[5]   In vitro activities of four novel triazoles against Scedosporium spp. [J].
Carrillo, AJ ;
Guarro, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) :2151-2153
[6]   Development of a murine model of cerebral aspergillosis [J].
Chiller, TM ;
Luque, JC ;
Sobel, RA ;
Farrokhshad, K ;
Clemons, KV ;
Stevens, DA .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (04) :574-577
[7]   Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum [J].
Cuenca-Estrella, M ;
Ruiz-Díez, B ;
Martínez-Suárez, JV ;
Monzón, A ;
Rodríguez-Tudela, JL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (01) :149-151
[8]  
DEHOOG GS, 1994, MYCOSES, V37, P71, DOI 10.1111/j.1439-0507.1994.tb00780.x
[9]   In vitro activities of 10 antifungal drugs against 508 dermatophyte strains [J].
Fernández-Torres, B ;
Carrillo, AJ ;
Martín, E ;
Del Palacio, A ;
Moore, MK ;
Valverde, A ;
Serrano, M ;
Guarro, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) :2524-2528
[10]  
Gosbell I. B., 1999, Clinical Microbiology and Infection, V5, P672, DOI 10.1111/j.1469-0691.1999.tb00513.x
123